Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Effects of Formulation Variables on Lung Dosimetry of Albuterol Sulfate Suspension and Beclomethasone Dipropionate Solution Metered Dose Inhalers.

Schroeter JD, Sheth P, Hickey AJ, Asgharian B, Price OT, Holt JT, Conti DS, Saluja B.

AAPS PharmSciTech. 2018 Jul;19(5):2335-2345. doi: 10.1208/s12249-018-1071-7. Epub 2018 Jun 1.

PMID:
29858973
2.

Influence of Formulation Factors on the Aerosol Performance of Suspension and Solution Metered Dose Inhalers: A Systematic Approach.

Sheth P, Sandell D, Conti DS, Holt JT, Hickey AJ, Saluja B.

AAPS J. 2017 Sep;19(5):1396-1410. doi: 10.1208/s12248-017-0095-3. Epub 2017 Jun 7.

PMID:
28593514
3.
4.

AKT regulates BRCA1 stability in response to hormone signaling.

Nelson AC, Lyons TR, Young CD, Hansen KC, Anderson SM, Holt JT.

Mol Cell Endocrinol. 2010 May 5;319(1-2):129-42. doi: 10.1016/j.mce.2010.01.019. Epub 2010 Jan 18.

5.

Detecting BRCA2 protein truncation in tissue biopsies to identify breast cancers that arise in BRCA2 gene mutation carriers.

Watson P, Lieberman R, Snyder C, Clark VJ, Lynch HT, Holt JT.

J Clin Oncol. 2009 Aug 20;27(24):3894-900. doi: 10.1200/JCO.2008.20.5211. Epub 2009 Jul 20.

6.

Oestrogen-mediated phosphorylation and stabilization of BRCA2 protein in breast.

Malone JL, Nelson AC, Lieberman R, Anderson S, Holt JT.

J Pathol. 2009 Feb;217(3):380-8. doi: 10.1002/path.2458.

7.

Restoration of CAPAN-1 cells with functional BRCA2 provides insight into the DNA repair activity of individuals who are heterozygous for BRCA2 mutations.

Holt JT, Toole WP, Patel VR, Hwang H, Brown ET.

Cancer Genet Cytogenet. 2008 Oct 15;186(2):85-94. doi: 10.1016/j.cancergencyto.2008.06.013.

8.

Rad51 overexpression rescues radiation resistance in BRCA2-defective cancer cells.

Brown ET, Holt JT.

Mol Carcinog. 2009 Feb;48(2):105-9. doi: 10.1002/mc.20463.

9.

Radiation enhances caspase 3 cleavage of Rad51 in BRCA2-defective cells.

Brown ET, Robinson-Benion C, Holt JT.

Radiat Res. 2008 May;169(5):595-601. doi: 10.1667/RR1129.1.

10.

Effects of BRCA1 transgene expression on murine mammary gland development and mutagen-induced mammary neoplasia.

Hoshino A, Yee CJ, Campbell M, Woltjer RL, Townsend RL, van der Meer R, Shyr Y, Holt JT, Moses HL, Jensen RA.

Int J Biol Sci. 2007 Apr 25;3(5):281-91.

11.

An amino-terminal motif functions as a second nuclear export sequence in BRCA1.

Thompson ME, Robinson-Benion CL, Holt JT.

J Biol Chem. 2005 Jun 10;280(23):21854-7. Epub 2005 Apr 4.

12.

Gene therapy for breast and ovarian cancer with BRCA1.

Tait DL, Jensen RA, Holt JT, Johnson DH, Gralow J, King MC.

Breast Dis. 1998 Apr;10(1-2):89-98.

PMID:
15687552
13.

Nutrient fluxes and budgets for the North West European Shelf from a three-dimensional model.

Proctor R, Holt JT, Allen JI, Blackford J.

Sci Total Environ. 2003 Oct 1;314-316:769-85.

PMID:
14499563
14.

Redox-sensitive interaction between KIAA0132 and Nrf2 mediates indomethacin-induced expression of gamma-glutamylcysteine synthetase.

Sekhar KR, Spitz DR, Harris S, Nguyen TT, Meredith MJ, Holt JT, Gius D, Marnett LJ, Summar ML, Freeman ML.

Free Radic Biol Med. 2002 Apr 1;32(7):650-62. Erratum in: Free Radic Biol Med 2002 Jul 31;33(1):149. Guis David [corrected to Gius David].

PMID:
11909699
15.

Gene therapy for carcinoma of the breast: Therapeutic genetic correction strategies.

Obermiller PS, Tait DL, Holt JT.

Breast Cancer Res. 2000;2(1):28-31. Epub 1999 Dec 17. Review.

16.

Preclinical studies of a new generation retroviral vector for ovarian cancer BRCA1 gene therapy.

Tait DL, Obermiller PS, Holt JT.

Gynecol Oncol. 2000 Dec;79(3):471-6.

PMID:
11104622
17.

Ovarian Cancer Gene Therapy with BRCA1-An Overview.

Obermiller PS, Holt JT.

Methods Mol Med. 2000;35:593-607. doi: 10.1385/1-59259-086-1:593.

PMID:
21390833
18.

Analysis of cancer gene functions through gene inhibition with antisense oligonucleotides.

Robinson-Benion C, Jensen RA, Holt JT.

Methods Enzymol. 2000;314:499-506. No abstract available.

PMID:
10565035
19.

Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability.

Tait DL, Obermiller PS, Hatmaker AR, Redlin-Frazier S, Holt JT.

Clin Cancer Res. 1999 Jul;5(7):1708-14.

20.

BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair.

Abbott DW, Thompson ME, Robinson-Benion C, Tomlinson G, Jensen RA, Holt JT.

J Biol Chem. 1999 Jun 25;274(26):18808-12.

22.

A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer.

Tait DL, Obermiller PS, Redlin-Frazier S, Jensen RA, Welcsh P, Dann J, King MC, Johnson DH, Holt JT.

Clin Cancer Res. 1997 Nov;3(11):1959-68.

23.

Ovarian cancer gene therapy.

Tait DL, Obermiller PS, Jensen RA, Holt JT.

Hematol Oncol Clin North Am. 1998 Jun;12(3):539-52. Review.

PMID:
9684097
24.

Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells.

Abbott DW, Freeman ML, Holt JT.

J Natl Cancer Inst. 1998 Jul 1;90(13):978-85.

PMID:
9665145
25.

Breast cancer genes: therapeutic strategies.

Holt JT.

Ann N Y Acad Sci. 1997 Dec 29;833:34-41. Review.

PMID:
9616738
26.

Antisense c-myc retroviral vector suppresses established human prostate cancer.

Steiner MS, Anthony CT, Lu Y, Holt JT.

Hum Gene Ther. 1998 Mar 20;9(5):747-55.

PMID:
9551622
29.

RAP-PCR using RNA from tissue microdissection.

Jensen RA, Page DL, Holt JT.

Methods Mol Biol. 1997;85:277-83. No abstract available.

PMID:
9276331
30.
31.

Gene therapy for the treatment of metastatic breast cancer by in vivo transduction with breast-targeted retroviral vector expressing antisense c-fos RNA.

Holt JT, Arteaga CB, Robertson D, Moses HL.

Hum Gene Ther. 1996 Jul 10;7(11):1367-80. No abstract available.

PMID:
8818724
32.
33.

BRCA1 is secreted and exhibits properties of a granin.

Jensen RA, Thompson ME, Jetton TL, Szabo CI, van der Meer R, Helou B, Tronick SR, Page DL, King MC, Holt JT.

Nat Genet. 1996 Mar;12(3):303-8.

PMID:
8589722
34.

Growth retardation and tumour inhibition by BRCA1.

Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, Jensen RA.

Nat Genet. 1996 Mar;12(3):298-302. Erratum in: Nat Genet 1998 May;19(1):102.

PMID:
8589721
35.

A 'senseless' immune response to DNA.

Holt JT.

Nat Med. 1995 May;1(5):407-8. No abstract available.

PMID:
7585081
36.

Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression.

Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT.

Nat Genet. 1995 Apr;9(4):444-50.

PMID:
7795653
37.

Antisense techniques.

Robinson-Benion C, Holt JT.

Methods Enzymol. 1995;254:363-75. No abstract available.

PMID:
8531698
38.

Identification of genes expressed in premalignant breast disease by microscopy-directed cloning.

Jensen RA, Page DL, Holt JT.

Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9257-61.

39.

Myristylation-dependent transactivation by FBR v-fos is regulated by C/EBP.

Jotte RM, Kamata N, Holt JT.

J Biol Chem. 1994 Jun 10;269(23):16383-96.

40.

Gene transplantation: combined antisense inhibition and gene replacement strategies.

Robinson-Benion C, Li YX, Holt JT.

Leukemia. 1994 Apr;8 Suppl 1:S152-5.

PMID:
8152283
41.
42.

In vivo regional delivery of retrovirally mediated foreign genes to rat liver cells: need for partial hepatectomy for successful foreign gene expression.

Moscioni AD, Rozga J, Neuzil DF, Overell RW, Holt JT, Demetriou AA.

Surgery. 1993 Mar;113(3):304-11.

PMID:
8382843
43.

Histopathology: old principles and new methods.

Holt JT, Jensen RA, Page DL.

Cancer Surv. 1993;18:115-33. Review.

PMID:
8012993
44.

Antisense promoter mapping. Inhibitory methods of transcriptional analysis.

Holt JT.

Ann N Y Acad Sci. 1992 Oct 28;660:88-94.

PMID:
1340160
45.

Platelet-derived growth factor regulation of fos stability correlates with growth induction.

Jackson JA, Holt JT, Pledger WJ.

J Biol Chem. 1992 Aug 25;267(24):17444-8.

46.

Transforming growth factor beta 1 regulation of c-myc expression, pRB phosphorylation, and cell cycle progression in keratinocytes.

M√ľnger K, Pietenpol JA, Pittelkow MR, Holt JT, Moses HL.

Cell Growth Differ. 1992 May;3(5):291-8.

47.

Differential induction of the c-fos promoter through distinct PDGF receptor-mediated signaling pathways.

Salhany KE, Robinson-Benion C, Candia AF, Pledger WJ, Holt JT.

J Cell Physiol. 1992 Feb;150(2):386-95.

PMID:
1310326
48.
49.

Antisense inhibition of c-myc expression reveals common and distinct mechanisms of growth inhibition by TGF beta and TNF alpha.

Robinson-Benion C, Salhany KE, Hann SR, Holt JT.

J Cell Biochem. 1991 Feb;45(2):188-95.

PMID:
2055946
50.

Myristylation alters DNA-binding activity and transactivation of FBR (gag-fos) protein.

Kamata N, Jotte RM, Holt JT.

Mol Cell Biol. 1991 Feb;11(2):765-72.

Supplemental Content

Support Center